Barclays Capital HealthCare Conference

John LeonardJohn LeonardSenior Vice President, Pharmaceuticals, Research and Development

Forward-Looking Statementg

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995, p p gincluding the planned separation of the research-based pharmaceutical company from the diversified medical products company and the expected financial results of the two companies after the separation. Abbott cautions that these forward-looking statements are subject to risks and uncertaintiesthat these forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward looking statements, and there is no assurance as to the timing of the planned separation or whether it will be completed. Economic, competitive governmental technological and other factors that may affectcompetitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2010 and in the interim reports filed on Form 10-Q for

b t t l i d d i t d b f Abb ttsubsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

2© 2012 Abbott

Pharmaceutical Pipeline Snapshot

30 Compounds currently in human trials

15 Biologics currently in pipeline (late Discovery – Phase III)

>20 Compounds or indications currently in Phase II or Phase III

• Numerous pipeline opportunities with breakthrough potential• Goal to bring to market products that demonstrate:

– Strong clinical performance– Patient benefit – Economic value

3© 2012 Abbott

R&D Productivityy

Enhanced clinical study designs

Expanded external validation

Better cross-functional input

Goal to achieve a success rate significantly higher than industry averagehigher than industry average

4© 2012 Abbott

Pharmaceutical Pipeline HighlightsImmunologygy

Numerous Approaches with Potential for Differentiated Efficacy and Safety

DVD-Ig• Proprietary platform enables two antibodies in single agent• Phase I currently underway

ABT 122: anti TNF/IL 17 (RA)– ABT-122: anti-TNF/IL-17 (RA)BT-061 (Partner: Biotest)• Novel anti-CD4 antibody; activates T-regulatory cells

– Currently in Phase IIa for RA and psoriasisCurrently in Phase IIa for RA and psoriasisGLPG0634 (Partner: Galapagos)• Next-generation, highly selective JAK1 inhibitor• Potential for better safety and efficacy profile vs. other JAK inhibitors in development

– Currently in Phase IIa for RAOther Early-Stage Oral Candidates• Evaluating early stage candidates, including: JAK1; SYK, next-generation AIMs

5© 2012 Abbott

Pharmaceutical Pipeline HighlightsBardoxolone

Bardoxolone: Potential Game-Changer in CKD Treatment Landscape

Disease Overview• Current treatments (non-specific) only modestly slow progression • Patients ultimately progress to end-stage disease/dialysis• Significant cost to healthcare systems worldwideBardoxolone Highlights (Partner: Reata)• Oral, first-in-class anti-inflammatory: Nrf2 activator• Improves kidney’s ability to filter and remove waste from the body (eGFR)• First-and-only treatment shown to reverse disease progression• Phase III program underway, enrolling ahead of forecast

– Primary endpoint: time to first event of composite endpoint (ESRD or CV death)• Expect Phase III results in 2013• Peak Year Opportunity: >$1BN

6© 2012 Abbott

pp y

Pharmaceutical Pipeline HighlightsDaclizumab

Daclizumab: Potential for High Efficacy, Manageable Safety in MS

Disease Overview• Disorder in which immune system attacks the myelin, which protects nerve fibers• Most common progressive and disabling neurological condition in young adults• $11BN market growing to more than $14BN by 2020Daclizumab Highlights (Partner: Biogen)

• In Phase III development for relapsing remitting MS (RRMS)• Current therapies have either marginal efficacy with nuisance side effects or high

efficacy and serious, unpredictable side effects (i.e. PML)• Daclizumab offers potential to deliver right balance of high efficacy, manageable safety• Phase IIb data promising; potential for annual relapse rate similar to other next-

generation therapies and possible incremental disability benefit• Phase III results expected in 2014, commercialization 2016• Peak Year Opportunity: >$1BN

7© 2012 Abbott

• Peak Year Opportunity: >$1BN

Pharmaceutical Pipeline HighlightsHCV Combination

HCV Combo: Opportunity for Vast Improvement Over Current Therapies

Disease Overview• 180MM people infected worldwide; more than 4MM newly diagnosed per year globally• Heterogeneous disease; number of genotypes and subtypes• $3BN market expected to grow 5-6X by 2019Abbott Program Highlights• Broad HCV program: Protease, Polymerase and NS5A inhibitors in development• Goal is three-fold:

– High cure rates in broadest range of patients– Significantly shorten and simplify course of therapy– Interferon-free

• Phase IIb program ongoing, enrolling well; studying various combinations of three MOA• Additional data presented this year will shed further light on our advancing program

P k Y O t it $2BN

8© 2012 Abbott

• Peak Year Opportunity: >$2BN

Pharmaceutical Pipeline Additional Late-Stage Highlightsg g g

• Several additional indications in development• Collectively represent ~$1BN peak opportunity

HUMIRA Additional Indications

Duodopa (LCIG)

• Collectively represent ~$1BN peak opportunityIndications

• Intestinal gel for advanced Parkinson’s disease• Infused directly into small intestine via portable pump

Elagolix

Duodopa (LCIG)

• Uniquely provides partial estrogen suppression

• Currently on market in Europe• U.S. pivotal data and registration submission in 2012

Elagolix (Partner: Neurocrine) • Phase II for uterine fibroids ongoing

• On track to start Phase III for endometriosis 1H12

• Currently in Phase III for multiple myelomaElotuzumab Currently in Phase III for multiple myeloma• Phase II results showed high response rates

Elotuzumab(Partner: BMY)

9© 2012 Abbott

Pharmaceutical PipelineSummary

• Unique and promising pipeline of proprietary pharmaceutical products

y

p– Highly prevalent conditions– Numerous medicines in development with breakthrough potential

P t ti l t d i i ifi t th f th h b d• Potential to drive significant growth for the new research-based pharmaceutical company

10© 2012 Abbott

Q&A

11© 2012 Abbott

Barclays Capital HealthCare Conference

John LeonardJohn LeonardSenior Vice President, Pharmaceuticals, Research and Development